SCHEMBL1005992

SCHEMBL1005992

CCCCCCCCCCCCCCOc1ccccc1C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.74
MEN1 O00255 2/20 0.74
LMNA P02545 2/20 0.74
CYP3A4 P08684 2/20 0.74
NR1I2 O75469 1/20 0.74
CHRM2 P08172 1/20 0.74
ADRA2A P08913 1/20 0.74
MAPT P10636 1/20 0.74
OPRK1 P41145 1/20 0.74
HTR2B P41595 1/20 0.74
SLC6A3 Q01959 1/20 0.74
HDAC6 Q9UBN7 1/20 0.74
PTPN11 Q06124 6/20 0.68
ALDH1A1 P00352 4/20 0.65
PTK2B Q14289 1/20 0.65
NPSR1 Q6W5P4 1/20 0.62
KDM4E B2RXH2 1/20 0.60
RECQL P46063 1/20 0.60
PTPN1 P18031 3/20 0.60
S1PR3 Q99500 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342176 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL2044840 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL18140779 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL18141371 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL3665313 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL1274781 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL527254 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL6575990 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL168816 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2
SCHEMBL112985 1.00 KMT2A (0.74) KMT2AMEN1LMNACYP3A4NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240099976-A1 BLENDED FORMULATIONS SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2024-03-28 US claimed
CN-115851337-B Preparation method of alkaline calcium alkyl salicylate 新乡市瑞丰新材料股份有限公司 2023-12-22 CN claimed
CN-117050034-A Multifunctional benzothiadiazole Schiff base luminescent liquid crystal and preparation and application thereof 云南大学 2023-11-14 CN claimed
CN-115851337-A Preparation method of alkaline calcium alkyl salicylate 新乡市瑞丰新材料股份有限公司 2023-03-28 CN claimed
EP-3954361-A1 MULTIPHASIC COMPOSITIONS Sequessome Technology Holdings Limited (MT) 2022-02-16 EP claimed
CN-112370377-A High-protection waterproof sunscreen cream and preparation method thereof 广州美莱洁化妆品开发有限公司 2021-02-19 CN claimed
US-20210007989-A1 MULTIPHASIC COMPOSITIONS SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2021-01-14 US claimed
US-20190167588-A1 BLENDED FORMULATIONS SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2019-06-06 US claimed
US-20180311148-A1 MULTIPHASIC COMPOSITIONS SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2018-11-01 US claimed
EP-3316856-A1 BLENDED FORMULATIONS Sequessome Technology Holdings Limited (MT) 2018-05-09 EP claimed
EP-3316857-A1 MULTIPHASIC COMPOSITIONS Sequessome Technology Holdings Limited (MT) 2018-05-09 EP claimed
WO-2017001617-A1 BLENDED FORMULATIONS SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2017-01-05 WO claimed
WO-2017001625-A1 MULTIPHASIC COMPOSITIONS SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2017-01-05 WO claimed
CN-101332157-B Cysteine derivatives AJINOMOTO KK 2012-01-11 CN claimed
CN-100453531-C Cysteine derivatives AJINOMOTO KK (JP) 2009-01-21 CN claimed
US-20260144736-A1 Aqueous Polymer Emulsion for Cosmetic, Method for Producing Same, and Cosmetic TOAGOSEI CO., LTD. (JP) 2026-05-28 US disclosed
US-12582590-B2 Transparent liquid composition and cosmetic containing said composition SEIWA KASEI COMPANY, LIMITED (JP) 2026-03-24 US disclosed
WO-1988009365-A1 DIESEL FUEL COMPOSITION EXXON CHEMICAL PATENTS, INC. (US) 1988-12-01 WO disclosed
EP-0293192-A1 Diesel fuel composition EXXON CHEMICAL PATENTS INC. (US) 1988-11-30 EP disclosed
EP-0239444-A1 Ferroelectric liquid crystal, process for its manufacture and its use in a liquid-crystal mixture THOMSON-CSF (FR) 1987-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12582590-B2 Transparent liquid composition and cosmetic containing said composition GK, CUTA, GHDC KMT2A 3227/4885MEN1 1200/4885LMNA 266/4885
US-20260144736-A1 Aqueous Polymer Emulsion for Cosmetic, Method for Producing Same, and Cosmetic MMAB, RARB, RXRB KMT2A 1273/4885MEN1 772/4885LMNA 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.